A study to determine whether non-pharmacological methods like Hormetic stressors can be used in the treatment of knee osteoarthritis
Not Applicable
- Conditions
- Health Condition 1: M179- Osteoarthritis of knee, unspecified
- Registration Number
- CTRI/2023/05/052202
- Lead Sponsor
- Dr Mahendra Suresh Sinai Kudchadker
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Adult in the age group of 40-70 years
2.Knee with KL (Kellgren Lawrence) grade II and III OA (Osteoarthritis).
Exclusion Criteria
1.Grade 4 OA KNEE
2.Age younger than 40 yrs and Older than 70 yrs
3.Any prior surgical intervention or intraarticular injections in the past year
- If patients did not follow atleast 2 of the 3 hormetic stressors for atleast for 6 weeks
- Co-morbidities which are at risk for hormetic therapy- IHD, Vasovagal syncope, DM type 1 etc.,
- Other ipsilateral joint deformities effecting clinical intervention and true assessment of effected knee.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Pain: <br/ ><br>a.VAS score <br/ ><br>2.Knee Functions: <br/ ><br>a.WOMAC Score <br/ ><br>b.Walking ability- 6 minute walk test <br/ ><br>c.Range of Motion of knee joint using Goniometer <br/ ><br>Timepoint: at day 1, 12 weeks and 16 weeks
- Secondary Outcome Measures
Name Time Method 1.Serum Inflammatory markers like ESR, CRP & IL6 and <br/ ><br>2.Synovial thickness whether nodular or diffuse, and effusion measured in suprapatellar and lateral and medial recesses using B mode multi frequency (7-12hz) linear array transducer Ultrasound in patients willing to do and consenting of their own accord. <br/ ><br>3.MRI and CT scan for measurement of cartilage thickness in a few randomized patients <br/ ><br>4.Leucocyte Telomere length in few random patients. <br/ ><br> <br/ ><br> <br/ ><br>Primary and secondary outcomes 1 and 2 will be mandatory while secondary outcome measure 3 and 4 will be optional in the study. <br/ ><br>Timepoint: at day 1, 12 weeks and 16 weeks